Be Biopharma
Cambridge
About Be Biopharma
Be Biopharma pioneers engineered B cell medicines aimed at improving treatments for conditions like Hemophilia B and cancer. Their innovative approach utilizes precision genome editing to create durable and effective cell therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $356.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Jan 2025)
- Website: be.bio
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/be-biopharma-96449 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.